Skip to Content Facebook Feature Image

Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion

Business

Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion
Business

Business

Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion

2026-05-28 21:25 Last Updated At:21:45

QINGDAO, China, May 28, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) has been named the No. 1 Chinese brand in global life science laboratory equipment sales and No. 1 in overseas sales in the same category, according to 2025 data published by Euromonitor International. The dual ranking places Haier Biomedical at the front of a competitive global field and caps a three-phase international expansion that has delivered a compound annual growth rate exceeding 20 percent.

Euromonitor International is one of the world's leading independent market research firms, and its rankings are widely used as benchmarks across global procurement and industry analysis. The two No. 1 positions cover total global sales revenue and overseas sales revenue measured among Chinese-owned brands in the life science laboratory equipment category. The rankings span all global markets, confirming that Haier Biomedical is competing at the highest level against established international manufacturers.

The rankings also carry practical weight for international partners. In a field where equipment reliability, regulatory compliance, and long-term service support are critical to procurement decisions, independent verification of market leadership provides an additional layer of confidence for institutions evaluating suppliers.

Haier Biomedical's international growth began with targeted projects, working directly with organizations including UNICEF and the WHO to solve specific unmet needs and building a leading position in solar-powered vaccine storage. From there, the company scaled its distribution network to cover 160 countries through more than 800 active dealer relationships. The current phase focuses on embedding full operational capabilities in key regions: local warehousing, sales, marketing, product planning, and R&D.

The company now operates overseas R&D centers in the UK, Italy, and Japan, each focused on specific product lines including centrifuges, cold chain and automation storage solutions, incubators, and biosafety cabinets. In the UK and continental Europe, dedicated product specialists in automation and centrifuge technology provide on-site support for GMP compliance, air safety, and sample purification, positioning Haier Biomedical as a laboratory workflow partner. Service standards developed in the US and UK are being replicated across the EU, Southeast Asia, and South Asia.

In Q1 2026, revenue in Germany, Australia, and Canada grew more than 50 percent, while Eastern Europe, South Asia, and Brazil each exceeded 100 percent year-on-year growth, with centrifuges and incubators both doubling in volume. In the pharmaceutical sector, Haier Biomedical is part of the supply chains of multiple leading pharmaceutical companies across key countries including Switzerland, Germany, Denmark, Italy, Singapore, the US, Israel, and India. The company's Ultra Energy series holds all eight top positions in the US Energy Star rankings for its category, making it the bestselling line in that segment.

Looking ahead, Haier Biomedical is set to deepen its localization investments and expand its product range, with the goal of helping global biopharmaceutical and life sciences laboratories improve efficiency and sustainability, as part of the company's vision to lead the world in delivering integrated life sciences tools and intelligent productivity platforms.

For more information, visit https://www.haiermedical.com/.

QINGDAO, China, May 28, 2026 /PRNewswire/ -- Haier Biomedical (SHA: 688139) has been named the No. 1 Chinese brand in global life science laboratory equipment sales and No. 1 in overseas sales in the same category, according to 2025 data published by Euromonitor International. The dual ranking places Haier Biomedical at the front of a competitive global field and caps a three-phase international expansion that has delivered a compound annual growth rate exceeding 20 percent.

Euromonitor International is one of the world's leading independent market research firms, and its rankings are widely used as benchmarks across global procurement and industry analysis. The two No. 1 positions cover total global sales revenue and overseas sales revenue measured among Chinese-owned brands in the life science laboratory equipment category. The rankings span all global markets, confirming that Haier Biomedical is competing at the highest level against established international manufacturers.

The rankings also carry practical weight for international partners. In a field where equipment reliability, regulatory compliance, and long-term service support are critical to procurement decisions, independent verification of market leadership provides an additional layer of confidence for institutions evaluating suppliers.

Haier Biomedical's international growth began with targeted projects, working directly with organizations including UNICEF and the WHO to solve specific unmet needs and building a leading position in solar-powered vaccine storage. From there, the company scaled its distribution network to cover 160 countries through more than 800 active dealer relationships. The current phase focuses on embedding full operational capabilities in key regions: local warehousing, sales, marketing, product planning, and R&D.

The company now operates overseas R&D centers in the UK, Italy, and Japan, each focused on specific product lines including centrifuges, cold chain and automation storage solutions, incubators, and biosafety cabinets. In the UK and continental Europe, dedicated product specialists in automation and centrifuge technology provide on-site support for GMP compliance, air safety, and sample purification, positioning Haier Biomedical as a laboratory workflow partner. Service standards developed in the US and UK are being replicated across the EU, Southeast Asia, and South Asia.

In Q1 2026, revenue in Germany, Australia, and Canada grew more than 50 percent, while Eastern Europe, South Asia, and Brazil each exceeded 100 percent year-on-year growth, with centrifuges and incubators both doubling in volume. In the pharmaceutical sector, Haier Biomedical is part of the supply chains of multiple leading pharmaceutical companies across key countries including Switzerland, Germany, Denmark, Italy, Singapore, the US, Israel, and India. The company's Ultra Energy series holds all eight top positions in the US Energy Star rankings for its category, making it the bestselling line in that segment.

Looking ahead, Haier Biomedical is set to deepen its localization investments and expand its product range, with the goal of helping global biopharmaceutical and life sciences laboratories improve efficiency and sustainability, as part of the company's vision to lead the world in delivering integrated life sciences tools and intelligent productivity platforms.

For more information, visit https://www.haiermedical.com/.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion

Haier Biomedical Achieves Double No. 1 Ranking in Euromonitor's Global Life Science Lab Equipment Report, Caps Three-Phase Global Expansion

OTTAWA, ON, May 29, 2026 /PRNewswire/ -- Gastops, a Canadian leader in intelligent condition monitoring and maintenance solutions, today announced it has been awarded a contract for FluidSIGHT™ under Canada's Innovation for Defence Excellence and Security (IDEaS) program as a Test Drives participant in the All Systems Go! challenge.

Test Drives enable the Department of National Defence (DND) and the Canadian Armed Forces (CAF) to evaluate innovative technologies in realistic operating environments to assess their potential to address future defence capability needs. As part of this effort, Gastops will further adapt and demonstrate its FluidSIGHT technology in support of advanced health and usage monitoring applications onboard military land vehicles, helping inform future capability decisions.

FluidSIGHT is a real-time oil condition, contamination, and wear monitoring system that provides continuous insight into the health of lubricated systems directly at the asset. FluidSIGHT allows operators to transition from periodic oil sampling to continuous, real-time condition awareness.

The IDEaS program has played a key role in advancing FluidSIGHT's technical maturity. Through participation in an IDEaS Competitive Projects challenge, Gastops has progressed FluidSIGHT from an early proof‑of‑concept to a deployable, testable system suitable for evaluation. The Test Drives phase represents a critical step in validating the technology's performance, integration readiness, and operational relevance alongside DND and CAF stakeholders.

"Being selected for IDEaS Test Drives reflects both the technical maturity of FluidSIGHT and its alignment with Canada's defence innovation priorities," said Shaun Horning, President and CEO at Gastops. "The IDEaS program has allowed us to systematically mature FluidSIGHT from concept to a product that can now be evaluated in a brand-new environment, military land vehicles, helping demonstrate how real-time oil condition awareness can improve equipment availability, safety, and maintenance decision‑making."

Gastops brings decades of experience delivering diagnostics, prognostics, and condition‑based maintenance solutions for mission‑critical platforms across aerospace, defence, marine, energy, and industrial sectors. The IDEaS Test Drives project builds on this foundation and supports Canada's objective to accelerate the adoption of innovative, Canadian-developed technologies in defence and security applications.

About Gastops

Gastops is the world's leading provider of intelligent condition monitoring solutions used in Aerospace, Defence, Energy, and Industrial applications to optimize the availability, performance, and safety of critical assets. We offer peace of mind to our customers with innovative online monitoring sensors, at-line analysis, complex modeling and simulation, world-class laboratory testing, engineering, design, and MRO services that predict performance to enable proactive operating decisions. We have been providing powerful insights into the condition of critical equipment since 1979. Gastops is the intelligence inside what moves you.

www.gastops.com 

Media Contacts: media@gastops.com, +1 (613) 744-3530

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Gastops FluidSIGHT™ Awarded IDEaS Test Drives Contract Under Canada's All Systems Go! Challenge

Gastops FluidSIGHT™ Awarded IDEaS Test Drives Contract Under Canada's All Systems Go! Challenge

Recommended Articles